Gary M. Clark
Keine laufenden Positionen mehr
Karriereverlauf von Gary M. Clark
Ehemalige bekannte Positionen von Gary M. Clark
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Cancer Therapy & Research Center Endowment | Corporate Officer/Principal | - | - |
Flagship Biosciences, Inc.
 Flagship Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO. | Direktor/Vorstandsmitglied | - | - |
| University of Kansas | Corporate Officer/Principal | - | - |
| University of Texas Health Center | Corporate Officer/Principal | - | - |
| Baylor College of Medicine | Corporate Officer/Principal | - | - |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 18.03.2008 | - |
Ausbildung von Gary M. Clark
| University of Washington | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 9 |
Operativ
| Corporate Officer/Principal | 6 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Consumer Services | 5 |
| Health Technology | 3 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
| Cancer Therapy & Research Center Endowment | Health Services |
Flagship Biosciences, Inc.
Flagship Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO. | Commercial Services |
- Börse
- Insiders
- Gary M. Clark
- Erfahrung
